GDPR: How to Navigate the Data Privacy Maze in Global Clinical Trials
"Understanding the Impact of EU's GDPR on Research and Patient Consent Across Borders"
The enforcement of the EU's General Data Protection Regulation (GDPR) has sent ripples across the globe, reaching as far as Australia. These regulations have shifted control of personal data back to individuals, impacting how data, even data previously consented to for clinical trials, is handled.
Experts like Anastassia Negrouk and Denis Lacombe have pointed out inconsistencies and uncertainties in GDPR guidance. Active clinical trials involving EU participants face challenges in meeting GDPR compliance, creating concerns about the continuation and validity of ongoing research.
This article explores how GDPR affects global clinical trials, focusing on patient consent, data management, and the need for clear guidelines to ensure research integrity and international collaboration.
Defining GDPR in Clinical Research
The GDPR is a complex European privacy and data protection law that took effect on May 25, 2018. It applies to human-subjects research involving clinical or medical studies. Personal data includes information relating to an identified or identifiable natural person, including identifiers, location data, and genetic, physiological, mental, economic, cultural, or social characteristics. The GDPR's application is further complicated by differences among countries in the European Economic Area.
From Regional Rules to Global Trials
Clinical trials increasingly operate across jurisdictions with different data-protection expectations. The United States framework includes HIPAA, while European research involving personal data is governed by the GDPR. Guidance for sponsors therefore addresses GDPR, HIPAA, and FDA expectations together when trials span multiple regions. This multi-region perspective is also relevant to AI-enabled analyses of clinical research data.
Decoding GDPR's Impact on Clinical Trials: Why It Matters
GDPR's reach extends beyond Europe, affecting how researchers worldwide collect, store, and use patient data in clinical trials. This regulation gives individuals more control over their personal data, impacting how consent is obtained and managed throughout a trial's duration.
- Annual Re-Consenting: Repeatedly seeking consent from participants can strain resources and create logistical challenges.
- Participant Dropouts: More complex consent processes may lead to participants withdrawing from studies.
- Data Storage Redesign: Providing participants with unfettered data access requires significant changes to data storage infrastructure.
Research Under Pressure
Recent scholarship has raised concerns that GDPR requirements could significantly impede medical data research. Williams's 2018 article, "GDPR—not just an EU regulation?", is cited in this discussion alongside work by Staunton, Slokenberga, and Mascalzoni published in 2019. Practical guidance responds by calling for data protection plans tailored to GDPR, HIPAA, and UK-GDPR requirements. It also recommends aligning practices with FDA, EMA, and MHRA expectations and incorporating privacy into standard operating procedures, training, and vendor management.
The Complexity of Compliance
Research in the European Union operates within a legal and ethical framework described as complex and divergent. The interaction among applicable rules creates particular challenges for GDPR compliance in clinical research. Clinical trials also involve protected health information under HIPAA, creating an additional layer where U.S. and European requirements intersect. Transparency of trial results can therefore raise privacy questions under the EU's GDPR 2016/679.
Overlapping Frameworks
Clinical research may be governed by GDPR, HIPAA, and UK-GDPR, each with its own scope and requirements. Comparative analysis of HIPAA and GDPR addresses who each framework covers, their legal bases, de-identification and pseudonymisation approaches, breach notification, participant rights, transfers, and contracts. These differences make it necessary for clinical-trial teams to understand the frameworks rather than treat them as interchangeable. Data protection planning must account for the specific regulatory environment governing the trial.
Navigating the Future: Collaboration and Clear Guidelines
EU collaborators play a crucial role in global clinical research. However, increased financial risk aversion may deter trial groups and industry from conducting studies involving EU participants, highlighting the need for solutions that streamline the process.
Retention Across Borders
Clinical-trial records may need to be retained for 25 years or more under regulatory guidance. GDPR nevertheless requires a documented justification for the retention period. That justification should be recorded in the Data Protection Impact Assessment. Long regulatory retention periods therefore need to be reconciled with GDPR's requirements for documented retention reasoning.
Managing Cross-Border Risk
A Kroll case study describes a GDPR and U.S. data-privacy assessment and action plan for a global biopharmaceutical company based in California. Another case study reports cross-border data-transfer challenges faced by a U.S. client and describes questions concerning international data protection, security, privacy, and compliance. These examples show that global clinical-data programs can require coordinated assessment and remediation across jurisdictions. GDPR also continues to shape how pharmaceutical companies manage clinical-trial data in the European Union, including cross-border compliance practices.
While improving the experience of clinical trial participants is a shared goal, regulations should not hinder international collaboration. The research community needs clear, unambiguous, and practical guidelines to navigate GDPR compliance effectively.
The path forward requires open communication, collaboration, and the development of compliance strategies that respect individual rights while preserving the integrity and progress of global clinical research. Compliance guidelines are paramount.